Advertisement
Canada markets close in 3 hours 13 minutes

  • S&P/TSX

    22,040.57
    +168.61 (+0.77%)
     

  • S&P 500

    5,070.42
    +59.82 (+1.19%)
     

  • DOW

    38,494.96
    +254.98 (+0.67%)
     

  • CAD/USD

    0.7316
    +0.0015 (+0.20%)
     

  • CRUDE OIL

    83.02
    +1.12 (+1.37%)
     

  • Bitcoin CAD

    91,196.90
    +879.53 (+0.97%)
     

  • CMC Crypto 200

    1,435.56
    +20.80 (+1.47%)
     

  • GOLD FUTURES

    2,341.60
    -4.80 (-0.20%)
     

  • RUSSELL 2000

    2,002.49
    +35.02 (+1.78%)
     

  • 10-Yr Bond

    4.5840
    -0.0390 (-0.84%)
     

  • NASDAQ

    15,691.42
    +240.11 (+1.55%)
     

  • VOLATILITY

    16.29
    -0.65 (-3.84%)
     

  • FTSE

    8,044.81
    +20.94 (+0.26%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • CAD/EUR

    0.6836
    -0.0014 (-0.20%)
     
MARKETS LIVE BLOG:

STOCKS EXTEND GAINS AS RESULTS SEASON KICKS INTO HIGH GEAR

Tech-focused investors prepare for fresh wave of earnings highlighted by struggling Tesla

Terns Pharmaceuticals to Present at H.C. Wainwright 5th Annual NASH Investor Conference

Terns Pharmaceuticals, Inc.
·1 min read

FOSTER CITY, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases, today announced that management will be presenting at the H.C. Wainwright 5th Annual NASH Investor Conference on Tuesday, October 12 at 2:30 p.m. ET.

A live audio webcast of the presentation will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcast will be archived on Terns’ website for 30 days following the presentation.

About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. Terns’ pipeline includes three clinical stage development programs including an FXR agonist, a VAP-1 inhibitor and a THR-β agonist, and a preclinical GLP-1 receptor agonist program. Terns is focused on developing combination therapies based on clinically validated and complementary mechanisms of action to address the multiple hepatic disease processes of NASH in order to drive meaningful clinical benefits for patients. For more information, please visit: www.ternspharma.com.

Contacts for Terns

Investors
Justin Ng
investors@ternspharma.com

Media
Jenna Urban
Berry & Company Public Relations
media@ternspharma.com